Literature DB >> 8137918

ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.

C Mollereau1, M Parmentier, P Mailleux, J L Butour, C Moisand, P Chalon, D Caput, G Vassart, J C Meunier.   

Abstract

Selective PCR amplification of human and mouse genomic DNAs with oligonucleotides encoding highly conserved regions of the delta-opioid and somatostatin receptors generated a human DNA probe (hOP01, 761 bp) and its murine counterpart (mOP86, 447 bp). hOP01 was used to screen a cDNA library from human brainstem. A clone (named hORL1) was isolated, sequenced and found to encode a protein of 370 amino acids whose primary structure displays the seven putative membrane-spanning domains of a G protein-coupled membrane receptor. The hORL1 receptor is most closely related to opioid receptors not only on structural (sequence) but also on functional grounds: hORL1 is 49-50% identical to the murine mu-, delta- and kappa-opioid receptors and, in CHO-K1 cells stably transfected with a pRc/CMV:hORL1 construct, ORL1 mediates inhibition of adenylyl cyclase by etorphine, a 'universal' (nonselective) opiate agonist. Yet, hORL1 appears not to be a typical opioid receptor. Neither is it a somatostatin or sigma (N-allylnormetazocine) receptor. mRNAs hybridizing with synthetic oligonucleotides complementary to mOP86 are present in many regions of the mouse brain and spinal cord, particularly in limbic (amygdala, hippocampus, septum, habenula, ...) and hypothalamic structures. We conclude that the hORL1 receptor is a new member of the opioid receptor family with a potential role in modulating a number of brain functions, including instinctive behaviours and emotions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137918     DOI: 10.1016/0014-5793(94)80235-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  206 in total

1.  Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.

Authors:  M Narita; H Mizoguchi; D E Oji; N J Dun; B H Hwang; H Nagase; L F Tseng
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Orphanin-FQ/nociceptin (OFQ/N) modulates the activity of suprachiasmatic nucleus neurons.

Authors:  C N Allen; Z G Jiang; K Teshima; T Darland; M Ikeda; C S Nelson; D I Quigley; T Yoshioka; R G Allen; M A Rea; D K Grandy
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

3.  Involvement of spinal protein kinase Cgamma in the attenuation of opioid mu-receptor-mediated G-protein activation after chronic intrathecal administration of [D-Ala2,N-MePhe4,Gly-Ol(5)]enkephalin.

Authors:  M Narita; H Mizoguchi; M Narita; H Nagase; T Suzuki; L F Tseng
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

4.  Opioid receptors from a lower vertebrate (Catostomus commersoni): sequence, pharmacology, coupling to a G-protein-gated inward-rectifying potassium channel (GIRK1), and evolution.

Authors:  M G Darlison; F R Greten; R J Harvey; H J Kreienkamp; T Stühmer; H Zwiers; K Lederis; D Richter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

5.  [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats.

Authors:  J P Redrobe; G Calo; R Guerrini; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 6.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

7.  Epidermal growth factor differentially augments G(i)-mediated stimulation of c-Jun N-terminal kinase activity.

Authors:  Anthony S L Chan; Yung H Wong
Journal:  Br J Pharmacol       Date:  2004-06-01       Impact factor: 8.739

8.  Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.

Authors:  Anna Siniscalchi; Donata Rodi; Michele Morari; Matteo Marti; Sabrina Cavallini; Silvia Marino; Lorenzo Beani; Clementina Bianchi
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 9.  Extranuclear signaling by ovarian steroids in the regulation of sexual receptivity.

Authors:  Paul E Micevych; Kevin Sinchak
Journal:  Horm Behav       Date:  2018-05-18       Impact factor: 3.587

Review 10.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.